PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript
…
43,298$
0,95%
Echtzeit-Aktienkurs PTC Therapeutics Inc.
Bid:
Ask:
Nachrichten zur PTC Therapeutics Inc. Aktie
PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains?
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…
PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program
PTC Therapeutics announces positive results from long-term treatment studies on vatiquinone for the treatment of Friedreich ataxia.…
PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
…
Earnings call: PTC Therapeutics updates on Q2 2024 financials & trials By Investing.com
Earnings call: PTC Therapeutics updates on Q2 2024 financials & trials…
PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript
…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Friedreichs Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx Therapeutics, Biogen, Lexeo Therapeutics, Larimar Therapeutics
The dynamics of Friedreichs ataxia market are anticipated to change as companies across the globe are thoroughly working toward the…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
PTC Therapeutics (PTCT) falls as the ECs advisory committee adopts a negative opinion regarding the renewal of the conditional marketing…
Biotech Stock Roundup: BIIBs Acquisition, PTCT, LRMR Gain on Updates & More News
Biogen (BIIB) and PTC Therapeutics, Inc. (PTCT) are in the spotlight following acquisition news and regulatory updates, respectively.…
PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna
…
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
PTC Therapeutics (PTCT) gains 21% on May 20 after the EC decided against adopting the negative CHMP opinion of January…
PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts
…
Earnings call: PTC Therapeutics reports strong first quarter financials By Investing.com
Earnings call: PTC Therapeutics reports strong first quarter financials…
PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript
…
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
PTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to resubmit its application for…
Earnings call: PTC Therapeutics reports strong growth and pipeline progress By Investing.com
Earnings call: PTC Therapeutics reports strong growth and pipeline progress…
PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript
…
PTC Therapeutics says total unaudited FY23 net revenue was about $946M
…
PTC Therapeutics posts 35% revenue growth in 2023 By Investing.com
PTC Therapeutics posts 35% revenue growth in 2023…
C4 Therapeutics stock soars on Merck partnership, license deal
C4 Therapeutics Inc shares surged 93% to $2.28 in early trading on Tuesday after the clinical-stage biopharmaceutical company announced an…
PTC Therapeutics issues EU, US regulatory updates on Translarna
…
PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript
…
PTC Therapeutics stock slides after Citi downgrades to Sell
…
: PTC Therapeutics stock jumps on royalty deal worth up to $1.5 billion
Shares gain 12% as PTC says proceeds of deal will be used to retire debt…
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with…
PTC Therapeutics (PTCT) Moves 5.3% Higher: Will This Strength Last?
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest…
PTC Therapeutics (PTCT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the…
PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -68.35% and 0.07%, respectively, for the quarter ended June 2023. Do…
PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
– Second-quarter 2023 total revenue of $214 million, representing 29% year-over-year growth – – Positive APHENITY and PIVOT-HD data readouts…
PTC Therapeutics Q2 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
PTC Therapeutics appoints Pierre Gravier as finance chief
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K PTC THERAPEUTICS, INC. For: Jul 13
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
SOUTH PLAINFIELD, N.J., July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Pierre Gravier…
PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin
SOUTH PLAINFIELD, N.J., July 11, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), announced today that the company will provide…
PTC Therapeutics seizure candidate vatiquinone misses primary endpoint
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K PTC THERAPEUTICS, INC. For: Jun 21
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Enveric, Zura top healthcare gainers; PTC Therapeutics, CohBar lead losers pack
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
PTC Therapeutics Shares Fall 21% as Co. Discontinues Some Programs in Gene Therapy
PTC Therapeutics Shares Fall 21% as Co. Discontinues Some Programs in Gene Therapy...…
Form 8-K PTC THERAPEUTICS, INC. For: May 20
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: CHIEF BUSINESS OFFICER verkauft Aktien von PTC Therapeutics im Wert von 118.791$
Pauwels, Eric - Vorstand - Tag der Transaktion: 2023-05-22...…
Insiderhandel: CHIEF BUSINESS OFFICER verkauft Aktien von PTC Therapeutics im Wert von 377.491$
Pauwels, Eric - Vorstand - Tag der Transaktion: 2023-05-19...…
PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
- Conference call and webcast to be held at 5:00 pm EDT - SOUTH PLAINFIELD, N.J., May 23, 2023 /PRNewswire/…
PTC Therapeutics Announces Strategic Pipeline Prioritization
- Preclinical and early research gene therapy programs discontinued - - Expected reductions of approximately 15% in residual 2023 OPEX…
Insiderhandel: CHIEF BUSINESS OFFICER verkauft Aktien von PTC Therapeutics im Wert von 46.267$
Pauwels, Eric - Vorstand - Tag der Transaktion: 2023-05-18...…
Insiderhandel: CHIEF BUSINESS OFFICER verkauft Aktien von PTC Therapeutics im Wert von 470.822$
Pauwels, Eric - Vorstand - Tag der Transaktion: 2023-05-17...…
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
- Highly statistically significant and clinically meaningful results - - 63% mean blood Phe reduction in primary analysis population (p...…